Showing Results for
- Academic Journals (20)
Search Results
- 20
Academic Journals
- 20
-
From:Mayo Clinic Proceedings (Vol. 97, Issue 2) Peer-ReviewedAbstract Objectives: To verify the analytical performance of a new mass spectrometry--based method, termed MASS-FIX, when screening for plasma cell disorders in a routine clinical laboratory. Patients and Methods:...
-
From:Journal of Hematology & Oncology (Vol. 9, Issue 1) Peer-ReviewedPurpose The purpose of this study was to better understand the efficacy and safety of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma(R/RMM). Methods...
-
From:Stem Cell Research & Therapy (Vol. 12, Issue 1) Peer-ReviewedDespite many recent advances on cancer novel therapies, researchers have yet a long way to cure cancer. They have to deal with tough challenges before they can reach success. Nonetheless, it seems that recently developed...
-
From:Journal of Clinical Investigation (Vol. 130, Issue 4) Peer-ReviewedMultiple myeloma (MM), a bone marrow-resident hematological malignancy of plasma cells, has remained largely incurable despite dramatic improvements in patient outcomes in the era of myeloma-targeted and immunomodulatory...
-
From:Oncology (Vol. 35, Issue 5) Peer-ReviewedThe second most common hematological malignancy in high-income countries, (1) multiple myeloma (MM) accounts for 1% of neoplastic diseases (1) and represents 18% of hematologic malignancies in the United States. (2) More...
-
From:Journal of Hematology & Oncology (Vol. 14, Issue 1) Peer-ReviewedThe pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are on the...
-
From:Journal of Oncology (Vol. 2020) Peer-ReviewedPanobinostat represents a potent oral nonselective pan-histone deacetylase inhibitor (HDAC) with activity in myeloma patients. It has been approved by the FDA and EMA in combination with bortezomib and dexamethasone for...
-
From:Journal of Hematology & Oncology (Vol. 13, Issue 1) Peer-ReviewedBackground Drug-loaded nanoparticles have established their benefits in the fight against multiple myeloma; however, ligand-targeted nanomedicine has yet to successfully translate to the clinic due to insufficient...
-
From:PLoS ONE (Vol. 15, Issue 1) Peer-ReviewedApolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) DNA cytosine deaminase 3B (A3B) is a DNA editing enzyme which induces genomic DNA mutations in multiple myeloma and in various other cancers....
-
From:Oncology (Vol. 34, Issue 7) Peer-ReviewedLEARNING OBJECTIVES Upon successful completion of this activity, you should be better prepared to: * Analyze the mechanistic properties of CAR T-cell therapies, including design characteristics that impact efficacy...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 40, Issue 1) Peer-ReviewedBackground Multiple myeloma (MM) is an incurable disease. The acquisition of resistance to drugs, including immunomodulatory drugs (IMiDs), has a negative effect on its prognosis. Cereblon (CRBN) is a key mediator of...
-
From:Oncology (Vol. 34, Issue 11) Peer-ReviewedThe development of novel therapies including proteasome inhibitors, monoclonal antibodies, and immunomodulatory drugs have significantly improved the prognosis and survival of patients with multiple myeloma. Despite the...
-
From:Journal of Hematology & Oncology (Vol. 12, Issue 1) Peer-ReviewedMultiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal...
-
From:Oncology (Vol. 30, Issue 10) Peer-ReviewedThe use of chimeric antigen receptor (CAR)-modified T cells is a promising antineoplastic immunotherapy. As discussed by Drs. Frey and Porter in this issue of ONCOLOGY,[1] it involves genetic manipulation of autologous...
-
From:Oncology (Vol. 34, Issue 3) Peer-ReviewedThirty years ago, patients with multiple myeloma faced a poor prognosis, with 5-year survival rates of approximately 25%. With the development of immunotherapy and targeted agents, that number has now almost doubled....
-
From:Oncology (Vol. 35, Issue 9) Peer-ReviewedFACULTY, STAFF, AND PLANNERS' DISCLOSURES In accordance with ACCME Guidelines, PER[R] has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep...
-
From:Journal of Oncology (Vol. 2018) Peer-ReviewedCentral nervous system involvement is a rare complication of multiple myeloma with extremely poor prognosis as it usually fails to respond to therapy. We present 13 cases diagnosed at two centers in Budapest and review...
-
From:BioMed Research International (Vol. 2018) Peer-ReviewedBackground. Refractory and relapsed multiple myeloma (RRMM) remains a clinical challenge. We compared the progression-free survival (PFS) of RRMM patients treated with lenalidomide and low dose dexamethasone plus...
-
From:Journal of Hematology & Oncology (Vol. 9, Issue 1) Peer-ReviewedElotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural...
-
From:Oncology (Vol. 34, Issue 11) Peer-ReviewedMultiple myeloma is the second most common hematologic malignancy in the United States, accounting for approximately 17% of all blood cancers. (1) It is characterized by unchecked production of monoclonal plasma cells in...